• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鸟嘌呤核苷酸对拮抗剂与A1腺苷受体结合的间接作用:内源性囊泡腺苷占据隐蔽结合位点。

Indirect effect of guanine nucleotides on antagonist binding to A1 adenosine receptors: occupation of cryptic binding sites by endogenous vesicular adenosine.

作者信息

Prater M R, Taylor H, Munshi R, Linden J

机构信息

Department of Internal Medicine (Cardiology), University of Virginia Health Center, Charlottesville 22908.

出版信息

Mol Pharmacol. 1992 Nov;42(5):765-72.

PMID:1435751
Abstract

Guanine nucleotides such as guanosine 5'-(3-O-thio)triphosphate (GTP gamma S) have been found to increase the binding of antagonists to adenosine A1 receptors. This response can be attributed either to a direct effect of GTP on receptors to increase antagonist affinity or to an indirect effect to decrease the affinity of receptors for a pool of endogenous adenosine that cannot be readily removed from membranes. In this study, adenosine content was measured in preparations of membranes and 3-[(3-cholamidopropyl)dimethylamino]-1-propanesulfonate (CHAPS)-solubilized receptors by a sensitive radioimmunoassay. In both preparations, pools of adenosine (2.5-10 pmol/mg of protein) were detected that were resistant to deamination by added adenosine deaminase (0.5-3 units/ml) unless membrane lipids were first dissolved in acetone. Electron microscopic examination of crude CHAPS-solubilized receptors revealed the existence of small vesicles (< 1 microns in diameter). Furthermore, most "solubilized" receptors were retained by a 0.1-microns filter. The effects of GTP gamma S were evaluated on the binding of an antagonist, 3-(4-amino-3-125I-phenethyl)-1-propyl-8-cyclopentylxanthine (125I-BW-A844U), to A1 receptors of bovine brain membranes, receptors solubilized in CHAPS (crude solubilized), or receptors partially co-purified with G proteins by agonist affinity chromatography (partially purified). GTP gamma S (10 microM) increased antagonist binding to membranes (20-50%) and crude CHAPS-solubilized receptors (> 200%) but increased binding to partially purified receptors by only 10-15%. GTP gamma S decreased agonist (125I-N6-aminobenzyladenosine) binding and increased antagonist Bmax, but did not significantly decrease (5%) the dissociation rate of the antagonist. Omission of Mg2+ mimicked the effects of GTP gamma S on agonist and antagonist binding and increased both the association and dissociation rates of 125I-BW-A844U. These data suggest that a Mg(2+)-dependent GTP gamma S-induced increase in antagonist binding to membranes and solubilized receptors is primarily due to unmasking of cryptic binding sites occupied by contaminating vesicular adenosine. These findings are consistent with the observation that adenosine receptor antagonists have been found to have little or no inverse agonist physiological effects in well oxygenated tissues.

摘要

已发现鸟嘌呤核苷酸,如鸟苷5'-(3-O-硫代)三磷酸(GTPγS),可增加拮抗剂与腺苷A1受体的结合。这种反应可能归因于GTP对受体的直接作用,以增加拮抗剂亲和力,或者归因于间接作用,即降低受体对内源性腺苷池的亲和力,而内源性腺苷池不易从膜中去除。在本研究中,通过灵敏的放射免疫测定法测量了膜制剂和3-[(3-胆酰胺丙基)二甲基氨基]-1-丙烷磺酸盐(CHAPS)溶解的受体中的腺苷含量。在这两种制剂中,均检测到腺苷池(2.5-10 pmol/mg蛋白质),除非膜脂质首先溶解在丙酮中,否则该腺苷池对添加的腺苷脱氨酶(0.5-3单位/ml)的脱氨作用具有抗性。对粗制CHAPS溶解的受体进行电子显微镜检查,发现存在小囊泡(直径<1微米)。此外,大多数“溶解”的受体被0.1微米的滤器截留。评估了GTPγS对拮抗剂3-(4-氨基-3-125I-苯乙基)-1-丙基-8-环戊基黄嘌呤(125I-BW-A844U)与牛脑膜A1受体、CHAPS中溶解的受体(粗制溶解物)或通过激动剂亲和色谱法与G蛋白部分共纯化的受体(部分纯化)结合的影响。GTPγS(10μM)增加了拮抗剂与膜(20-50%)和粗制CHAPS溶解的受体(>200%)的结合,但仅使与部分纯化受体的结合增加了10-15%。GTPγS降低了激动剂(125I-N6-氨苄基腺苷)的结合并增加了拮抗剂的Bmax,但并未显著降低(5%)拮抗剂的解离速率。省略Mg2+模拟了GTPγS对激动剂和拮抗剂结合的影响,并增加了125I-BW-A844U的结合和解离速率。这些数据表明,Mg(2+)依赖性的GTPγS诱导的拮抗剂与膜和溶解受体结合的增加主要是由于被污染的囊泡腺苷占据的隐蔽结合位点被暴露。这些发现与以下观察结果一致,即在充分氧合的组织中,腺苷受体拮抗剂几乎没有或没有反向激动剂的生理作用。

相似文献

1
Indirect effect of guanine nucleotides on antagonist binding to A1 adenosine receptors: occupation of cryptic binding sites by endogenous vesicular adenosine.鸟嘌呤核苷酸对拮抗剂与A1腺苷受体结合的间接作用:内源性囊泡腺苷占据隐蔽结合位点。
Mol Pharmacol. 1992 Nov;42(5):765-72.
2
Co-purification of A1 adenosine receptors and guanine nucleotide-binding proteins from bovine brain.从牛脑中共同纯化A1腺苷受体和鸟嘌呤核苷酸结合蛋白。
J Biol Chem. 1989 Sep 5;264(25):14853-9.
3
125I-BW-A844U, an antagonist radioligand with high affinity and selectivity for adenosine A1 receptors, and 125I-azido-BW-A844U, a photoaffinity label.125I-BW-A844U,一种对腺苷A1受体具有高亲和力和选择性的拮抗剂放射性配体,以及125I-叠氮基-BW-A844U,一种光亲和标记物。
Mol Pharmacol. 1988 Jun;33(6):585-91.
4
Agonist radioligand interactions with the solubilized porcine atrial A1 adenosine receptor.
Mol Pharmacol. 1989 Apr;35(4):450-7.
5
Interaction of purified bovine brain A1-adenosine receptors with guanine nucleotide-binding proteins of human platelet membranes following reconstitution.
Mol Pharmacol. 1990 Aug;38(2):170-6.
6
Regional differences in the effect of guanine nucleotides on agonist and antagonist binding to adenosine A1-receptors in rat brain, as revealed by autoradiography.通过放射自显影术揭示鸟嘌呤核苷酸对大鼠脑中激动剂和拮抗剂与腺苷A1受体结合作用的区域差异。
Neuroscience. 1990;34(3):759-69. doi: 10.1016/0306-4522(90)90180-c.
7
The effects of saponin on the binding and functional properties of the human adenosine A1 receptor.皂苷对人腺苷A1受体结合及功能特性的影响。
Br J Pharmacol. 1996 Apr;117(7):1521-9. doi: 10.1111/j.1476-5381.1996.tb15316.x.
8
Interactions of purified bovine brain A1-adenosine receptors with G-proteins. Reciprocal modulation of agonist and antagonist binding.纯化的牛脑 A1 - 腺苷受体与 G 蛋白的相互作用。激动剂和拮抗剂结合的相互调节。
Biochem J. 1991 May 1;275 ( Pt 3)(Pt 3):651-6. doi: 10.1042/bj2750651.
9
On the ability of endogenous adenosine to regulate purine nucleoside receptor binding of antagonists in smooth muscle membranes.内源性腺苷调节平滑肌膜中拮抗剂嘌呤核苷受体结合的能力。
J Pharmacol Exp Ther. 1990 Nov;255(2):886-92.
10
Reciprocal modulation of agonist and antagonist binding to A1 adenosine receptors by guanine nucleotides is mediated via a pertussis toxin-sensitive G protein.鸟嘌呤核苷酸对激动剂和拮抗剂与A1腺苷受体结合的相互调节是通过一种百日咳毒素敏感的G蛋白介导的。
J Pharmacol Exp Ther. 1988 Sep;246(3):1194-200.

引用本文的文献

1
Allosteric coupling from G protein to the agonist-binding pocket in GPCRs.G蛋白偶联受体中从G蛋白到激动剂结合口袋的变构偶联。
Nature. 2016 Jul 7;535(7610):182-6. doi: 10.1038/nature18324. Epub 2016 Jun 29.
2
Afferent arteriolar vasodilator effect of adenosine predominantly involves adenosine A2B receptor activation.腺苷对入球小动脉的血管舒张作用主要涉及腺苷 A2B 受体的激活。
Am J Physiol Renal Physiol. 2010 Aug;299(2):F310-5. doi: 10.1152/ajprenal.00149.2010. Epub 2010 May 12.
3
An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
一种研究内源性大麻素信号传导的优化方法:反对大鼠脑腺苷A1和大麻素CB1受体组成性活性的证据。
Br J Pharmacol. 2003 Dec;140(8):1451-9. doi: 10.1038/sj.bjp.0705577. Epub 2003 Nov 17.
4
Palmitoylation of the recombinant human A1 adenosine receptor: enhanced proteolysis of palmitoylation-deficient mutant receptors.重组人A1腺苷受体的棕榈酰化:棕榈酰化缺陷型突变受体的蛋白水解增强
Biochem J. 1999 Sep 1;342 ( Pt 2)(Pt 2):387-95.
5
Alkylxanthine adenosine antagonists and epileptiform activity in rat hippocampal slices in vitro.烷基黄嘌呤腺苷拮抗剂与体外大鼠海马切片中的癫痫样活动
Exp Brain Res. 1997 Feb;113(2):303-10. doi: 10.1007/BF02450328.
6
The effects of saponin on the binding and functional properties of the human adenosine A1 receptor.皂苷对人腺苷A1受体结合及功能特性的影响。
Br J Pharmacol. 1996 Apr;117(7):1521-9. doi: 10.1111/j.1476-5381.1996.tb15316.x.
7
The amphiphilic peptide adenoregulin enhances agonist binding to A1-adenosine receptors and [35S]GTP gamma S to brain membranes.两亲性肽腺调节素增强激动剂与A1 - 腺苷受体的结合以及[35S]GTPγS与脑膜的结合。
Cell Mol Neurobiol. 1995 Aug;15(4):465-93. doi: 10.1007/BF02071881.
8
Solubilized rabbit striatal A2a-adenosine receptors: stability and antagonist binding.可溶性兔纹状体A2a - 腺苷受体:稳定性与拮抗剂结合
Arch Biochem Biophys. 1993 Sep;305(2):611-7. doi: 10.1006/abbi.1993.1469.
9
A1 adenosine receptor inhibition of cyclic AMP formation and radioligand binding in the guinea-pig cerebral cortex.豚鼠大脑皮层中A1腺苷受体对环磷酸腺苷形成及放射性配体结合的抑制作用。
Br J Pharmacol. 1994 Dec;113(4):1501-7. doi: 10.1111/j.1476-5381.1994.tb17166.x.